Envestnet Asset Management
AKBA icon

Envestnet Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Envestnet Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,500
Closed -$16.8K – 4217
2024
Q2 		$16.8K Hold
16,500
– – ﹤0.01% 4144
2024
Q1 		$30.2K Buy
16,500
+2,500
+18% +$4K ﹤0.01% 4129
2023
Q4 		$17.4K Sell
14,000
-274
-2% -$279 ﹤0.01% 4023
2023
Q3 		$16.3K Buy
14,274
+274
+2% +$352 ﹤0.01% 3982
2023
Q2 		$12.8K Buy
+14,000
New +$13.5K ﹤0.01% 3934
2018
Q3 		– Sell
-2,025
Closed -$20K – 1274
2018
Q2 		$20K Sell
2,025
-217
-10% -$2.17K ﹤0.01% 2419
2018
Q1 		$21K Sell
2,242
-109
-5% -$1.52K ﹤0.01% 2354
2017
Q4 		$35K Buy
2,351
+243
+12% +$4.03K ﹤0.01% 2411
2017
Q3 		$41K Buy
2,108
+134
+7% +$2.06K ﹤0.01% 2329
2017
Q2 		$28K Sell
1,974
-15
-0.8% -$190 ﹤0.01% 2522
2017
Q1 		$18K Buy
1,989
+868
+77% +$8.47K ﹤0.01% 2684
2016
Q4 		$12K Sell
1,121
-647
-37% -$5.57K ﹤0.01% 2742
2016
Q3 		$16K Sell
1,768
-179
-9% -$1.52K ﹤0.01% 2835
2016
Q2 		$15K Sell
1,947
-420
-18% -$3.67K ﹤0.01% 2997
2016
Q1 		$21K Sell
2,367
-510
-18% -$4.13K ﹤0.01% 2953
2015
Q4 		$37K Buy
+2,877
New +$29.4K ﹤0.01% 2747

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Envestnet Asset Management's AKBA Position: Q3 2024 in Review

Envestnet Asset Management sold out of Akebia Therapeutics (AKBA) in Q3 2024, closing a stake of 16,500 shares — an estimated $16.8K sold.

Envestnet Asset Management first reported a position in AKBA in Q4 2015 and held it in 16 quarters. The position peaked at $41K in Q3 2017. 114 funds tracked by Wall St. Rank hold AKBA as of Q3 2024.

  • Envestnet Asset Management reported no remaining Akebia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Envestnet Asset Management sold 16,500 Akebia Therapeutics shares in Q3 2024, an estimated $16.8K.
  • Envestnet Asset Management first reported a position in Akebia Therapeutics in Q4 2015 and held it in 16 quarters.
  • Envestnet Asset Management's Akebia Therapeutics position peaked at $41K in Q3 2017.
  • 114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2024.

Based on Envestnet Asset Management's 13F filing for Q3 2024, filed 7 Nov 2024.